Photocure Q2 2026 results and acquisition
Analysis based on 6 articles · First reported Jul 29, 2026 · Last updated Jul 29, 2026
Photocure's steady revenue growth and strategic acquisitions position it for long-term expansion in bladder cancer diagnostics. The raised guidance and FDA reclassification catalyst may boost investor sentiment, though near-term profitability remains constrained by R&D investments.
Photocure ASA reported its second quarter 2026 financial results on July 29, 2026. Hexvix/Cysview revenues reached NOK 140.0 million (Q2 2025: NOK 135.6 million), with adjusted EBITDA of NOK 27.2 million (Q2 2025: NOK 27.0 million). Total revenues were NOK 142.5 million. The company raised its 2026 product revenue growth guidance to 8%-11% on a constant currency basis. Key strategic developments include the acquisition of Vesica Health, which developed the AssureMDx urine-based biomarker test for bladder cancer detection; a research collaboration with Artera to evaluate AI-enabled digital pathology; and the U.S. FDA's confirmation of plans to reclassify blue-light cystoscopy equipment in H2 2026. Photocure also installed 6 new Saphira towers in the U.S. and had 436 active U.S. accounts, up 20% year-over-year.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard